ArticleSAGE open medicine2025
Quantification of anterior scleral thickness in Posner-Schlossman syndrome.
Article in SAGE open medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate changes in anterior scleral thickness (AST) in patients with Posner-Schlossman Syndrome (PSS). Methods: Sixty-two patients with PSS were enrolled. AST was measured using swept-source optical coherence tomography at 0 mm (AST0), 1 mm (AST1), 2 mm (AST2), and 3 mm (AST3) from the scleral spur. Results: AST0, AST1, AST2, and AST3 were significantly reduced in PSS-affected eyes compared with that in fellow eyes. Furthermore, we divided patients into two subgroups based on the course of PSS: the short-term (PSS course < 1 year) subgroup and the long-term (PSS course ⩾ 1 year) subgroup. In the short-term subgroup, no significant differences in AST parameters (AST0, AST1, AST2, and AST3) were observed in PSS-affected and fellow eyes, while in the long-term subgroup, all the AST parameters (AST0, AST1, AST2, and AST3) were significantly reduced in PSS-affected eyes compared with that in fellow eyes. Conclusions: PSS-affected eyes demonstrated significantly reduced AST compared with that in fellow eyes. Moreover, a significant reduction of the AST was observed in long-term PSS-affected eyes, but not in short-term PSS-affected eyes. This indicates that changes in AST in PSS are time-dependent and progressive. Significant reduction of the AST is observed only after a certain period of time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.